Does the piperacillin minimum inhibitory concentration for pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 799-806

  Tamma, Pranita D ^a   Turnbull, Alison E ^b   Milstone, Aaron M ^a,b   Hsu, Alice J ^c   Carroll, Karen C ^d   Cosgrove, Sara E ^b,e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d Department of Pathology   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; PIPERACILLIN;

ADOLESCENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; DRUG TREATMENT FAILURE; GRAM NEGATIVE SEPSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865492132     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis545     Document Type: Article

References (30)

1. Clinical and Laboratory Standards Institute. Summary minutes: Subcommittee on Antimicrobial Susceptibility Testing. Available at: http://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/ ArchiveofPreviousEvents/ASTJanuary2011.pdf. Accessed 8 January 2012.
2. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982; 4:294-301.
3. Giamarellou H, Zissis NP, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 25:534-6. (Pubitemid 14129626)
4. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997; 41:95-100. (Pubitemid 26428140)
5. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27(Suppl 2):S24-8. (Pubitemid 29440615)
6. Wu YL, Scott EM, Po AL, Tariq VN. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 389-92. (Pubitemid 29425692)
7. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1:CD003344.
8. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005; 5:192-3; discussion 3-4.
9. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011; 37:491-503.
10. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48:4718-24. (Pubitemid 39577677)
11. Yang MA, Lee J, Choi EH, Lee HJ. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes. J Korean Med Sci 2011; 26:612-8.
12. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-93.
13. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133-64.
14. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
15. van Delden C. Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 2007; 30(Suppl 1): S71-5.
16. Costa GA, Delgado AF, Ferraro A, Okay TS. Application of the pediatric risk of mortality (PRISM) score and determination of mortality risk factors in a tertiary pediatric intensive care unit. Clinics (Sao Paulo) 2010; 65:1087-92.
17. Garcia L. Clinical microbiology procedures handbook. 3rd ed. Washington, DC: American Society for Microbiology, 2010.
18. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002; 44:51-7.
19. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007; 58: 337-44. (Pubitemid 47017635)
20. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther 2005; 27:1820-30. (Pubitemid 41815233)
21. Yamagishi Y, Terada M, Ohki E, Miura Y, Umemura T, Mikamo H. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa. J Infect Chemother 2012; 18:127-9.
22. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillintazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46:862-7. (Pubitemid 351417187)
23. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat Rev Microbiol 2004; 2:289-300. (Pubitemid 39490099)
24. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009; 53:379-85.
25. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723-5. (Pubitemid 47295515)
26. McGettigan SE, Andreacchio K, Edelstein PH. Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases. J Clin Microbiol 2009; 47:785-6.
27. Rodriguez-Bano J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamaseproducing Escherichia coli. Clin Microbiol Infect 2011; doi: 10.1111/j.1469-0691.2011.03673.
28. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20th information supplement (June 2010 update). M100-S20. Wayne, PA: CLSI. 2010.
29. Landman D, Salamera J, Singh M, Quale J. Accuracy of carbapenem nonsusceptibility for identification of KPC-possessing Enterobacteriaceae by use of the revised CLSI breakpoints. J Clin Microbiol 2011; 49:3931-3.
30. Jones RN, Stilwell MG, Rhomberg PR, Sader HS. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis 2009; 65:331-4.